Total: $228.65M | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details |
Aeolus |
Private placement of stock and warrants |
10S and 11W |
$5 |
The financing was led by Efficacy Capital; 7M five- year warrants are exercisable at $0.75 per share; also, Efficacy got 4M one-year warrants exercisable at $0.50 per share (6/6) |
Bioject |
Private placement of stock and notes |
N/A |
$5.75 |
Affiliates of Sanders Morris Harris are purchasing $4.5M of Series E preferred stock, while Partners for Growth LP is buying $1.5M of convertible notes (6/1) |
Cell |
Equity financing commitment |
N/A |
N/A |
Societe Generale agreed to purchase up to $55M of registered CTI stock over two years, shares it would sell on the Italian market; CTI would determine the timing and amount of any sales (6/21) |
Clinical Data |
Private placement of stock and warrants |
1.04S and 0.52W |
$17 |
The securities were sold to institutional and other accredited investors; details were not disclosed (6/14) |
CombiMatrix |
Equity financing commitment |
N/A |
N/A |
Cornell Capital Partners agreed to purchase up to $50M of CombiMatrix stock over two years at a 2.5% discount to the market price; CombiMatrix will determine the timing and amount of any sales (6/15) |
Corgentech |
Equity financing commitment |
N/A |
N/A |
Azimuth Opportunity Ltd. agreed to purchase up to $30M in Corgentech stock over two years, at a small discount to the market price; any sales would be made at Corgentech's discretion (6/20) |
ExonHit |
Private placement of stock and warrants |
1S and 0.1W |
€6.5 ($8.1) |
The shares were sold at €6.50 each; the one-year warrants are exercisable at €7.80 per share (6/16) |
Genaera |
Registered direct offering |
35.6S and 26.7W |
$25 |
Units were sold at $0.70385 each; the warrants are exercisable at $0.6101 per share; Banc of America Securities LLC was lead placement agent; Fortis Securities LLC was co- lacement agent (6/29) |
Genelabs |
Private placement of stock and warrants |
6.1S and 2.5W |
$9 |
Shares are being sold at $1.42 each, and the warrants at $0.125 per underlying share; the warrants are exercisable at $1.42 per share (6/27) |
Generex |
Private placement of securities/ warrants exercise |
3.4S and 2.56W; 4.36S |
$13.5 |
Shares in a private placement were sold at $2.05 each; five-year warrants in that deal are exercisable at $2.45 per share; also, investors exercised $6.5M in warrants to purchase 4.36M shares (6/2) |
ISTA |
Private placement of convertible notes |
N/A |
$40 |
The three-year, 8% notes have an initial conversion price of $7.75 per share (6/22) |
Lexicon |
Equity financing commitment |
N/A |
N/A |
Azimuth Opportunity Ltd. agreed to purchase up to $75M of registered Lexicon stock over 18 months, at a small discount to the market price; Lexicon would determine the timing and amounts (6/13) |
Peregrine |
Private placement of stock |
9.286S |
$13 |
The shares were sold from a shelf registration to the Double U Master Fund LP (6/19) |
ProMetic Life |
Private placement of stock |
29.6S |
C$10.8 ($9.7) |
The private placement of subordinate voting shares was made in deal with JPMorgan and Third Point LLC (6/2) |
Vectura |
Private placement of stock |
52.94S |
£45 ($82.6) |
The placement with institutional investors is being fully underwritten by Piper Jaffray (6/28) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. |